Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2)
Authors' conclusion
Antibody persistence was longer in the Pfizer group due to a higher peak antibody level following second vaccination with levels of protection in IMID on DMARD therapy similar to controls except in those on tsDMARDs where it was lower.
Study context
- Population
- Patients with immune-mediated inflammatory diseases (IMID) on DMARD therapy and controls vaccinated with two doses of ChAdO1nCov-19 (AZ) or BNT162b (Pfizer)
- Participants
- 175 patients
- Comparison
- DMARD withhold vs continue vs controls, after AZ or Pfizer vaccination and mRNA booster
- Outcome
- SARS-CoV2 antibody decay kinetics after two doses of AZ or Pfizer and response after mRNA booster
- Follow-up
- 6 months
Main finding
As reported in the abstract
Seropositive 6 months after initial AZ vaccination
- P across groups
- P = 0.756
Further findings
| Outcome | Values | P value |
|---|---|---|
| Seropositive 6 months after initial Pfizer vaccination | Withhold 91.4% · Continue 100% · Control 100% | |
| Mean SARS-CoV-2 antibody level, tsDMARD continuing therapy vs control | tsDMARD (continued) mean 2.2 U/mL · Control mean 4.8 U/mL | P = 0.010 |
| Mean time until loss of protective antibodies, IMID | AZ mean 61 days · Pfizer mean 137.5 days | |
| Time until loss of protective antibody titres by DMARD class, AZ | csDMARD 68.3 days · bDMARD 71.8 days · tsDMARD 64.0 days | |
| Time until loss of protective antibody titres by DMARD class, Pfizer | csDMARD 185.5 days · bDMARD 137.5 days · tsDMARD 116.0 days |
- Seropositive 6 months after initial Pfizer vaccination — P across groups
- p=0.226
Seroconversion after booster
- Seroconversion rates in all three intervention categories
- 100%
Original publication
Antibody response to the COVID-19 ChAdOx1nCov-19 and BNT162b vaccines after temporary suspension of DMARD therapy in immune-mediated inflammatory disease: an extension study (RESCUE 2). RMD Open. Published 2 March 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →